医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

CDISC Teams Up with Microsoft to Develop Open-Source Software for the Clinical Research Community

2021年06月01日 PM08:08
このエントリーをはてなブックマークに追加


 

AUSTIN, Texas

CDISC is teaming up with Microsoft to develop the CDISC Open Rules Engine (CORE), open-source software that executes machine-readable CDISC Conformance Rules. The global clinical research community will be able to leverage the CORE software to test study data for conformance to CDISC standards as well as regulatory and sponsor-specific conformance rule sets.

CDISC Conformance Rules as well as regulatory agency rules provide a critical quality check in ensuring study data conform to CDISC standards. An emerging industry best practice is to use Conformance Rules on an ongoing basis, throughout the study, to keep the data as close to submission ready as possible and to ensure quality in all data exchange scenarios. The free and open, Microsoft Azure-based CORE will execute Conformance Rules retrieved from the CDISC Library against standardized clinical research data and produce a report detailing the findings, which will allow researchers to receive, process, and review study data more efficiently and effectively.

“We are excited to work with Microsoft on another important initiative that extends our current work in support of standards-based process automation,” said Sam Hume, CDISC VP, Data Science. “We look forward to building a community around CORE that will collaborate to create new innovative features and solutions.”

“Microsoft is pleased to expand our work with CDISC to build the next generation CDISC Open Source Rules Engine to support Pharma Industry’s digital transformation goals and ultimately accelerate time to market for life saving therapies.” –Patty Obermaier, VP of Health and Life Sciences, Microsoft US.

To support and grow a community of open-source software developers, CDISC has initiated the CDISC Open Source Alliance (COSA). Several CDISC member organizations as well as individual developers have already committed to participate in COSA. Microsoft will provide ongoing guidance. Once released, CORE will become a COSA project supported by a global team of open-source developers and CDISC. A key component of COSA is community development.

CDISC collaborated with Microsoft on the Azure-based CDISC Library and CDISC 360, two projects that support standards-based process automation throughout the clinical research data lifecycle.

ABOUT CDISC
CDISC creates clarity in clinical research by convening a global community to develop and advance data standards of the highest quality. Required by the United States Food and Drug Administration (FDA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), recommended by the China National Medical Products Administration (NMPA) and adopted by the world’s leading research organizations, CDISC standards enable the accessibility, interoperability, and reusability of data. With the help of CDISC standards, the entire research community can maximize the value of data for more efficient and meaningful research that has invaluable impact on global health. CDISC is a 501(c)(3) global nonprofit charitable organization with administrative offices in Austin, Texas, with hundreds of employees, volunteers, and member organizations around the world. https://www.cdisc.org/

View source version on businesswire.com: https://www.businesswire.com/news/home/20210601005147/en/

CONTACT

Ann P. White

+1.512.363.5826

awhite@cdisc.org

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration
  • DKT International Implements Traditional and New Forms of Marketing in Africa, South America, and Southeast Asia to Expand Access to Contraceptives
  • オルガノンが計画外妊娠をめぐり世界規模の対話の喚起を目指す
  • IHMA Opens Microbiology Reference Laboratory in Shanghai, China to Further Support Global Anti-Infective Product Discovery and Development
  • Cyclica and IMPACT Therapeutics Team Up to Advance Differentiated Anti-cancer Drug Development